In second-line lymphoma – a setting where Breyanzi and Yescarta have already succeeded – Kymriah fails to beat stem cell transplant.
The latest deal over a CD47 asset has got investors wondering who could be next.
Fibrogen’s controversial anaemia pill becomes the latest example of markedly different regulatory stances taken in Europe and the US.
Since 2016 drug developers have spent $23.6bn in-licensing cancer projects, almost half of the sector’s up-front bill.
Mid-stage data with lenacapavir in treatment-naive patients justify pushing on; as for combos, Gilead is keeping its options open.
The company’s second foray with a PI3K inhibitor shows signs of additive activity, but investors punish it all the same.
GLPG3970 is biologically inert in ulcerative colitis and rheumatoid arthritis, so Galapagos’s search for something better goes on.